Melanoma

This phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…

Researchers are testing whether adding the chemotherapy drug irinotecan to the immunotherapy pembrolizumab helps people with metastatic or recurrent melanoma that cannot be removed by surgery. The trial enrolls adults whose cancer has returned at least six months after adjuvant p…

Researchers are testing whether adding an experimental DNA vaccine called iSCIB1+ to standard immunotherapy drugs nivolumab and ipilimumab helps people with advanced melanoma that cannot be removed by surgery. About 550 participants will be randomly assigned to receive either the…

This study tests whether giving two immunotherapy drugs (fianlimab and cemiplimab) before surgery can shrink melanoma tumors in people with stage IIIB to IV melanoma. About 35 adults will receive the drugs, then have surgery to remove any remaining cancer. The main goal is to see…

Researchers are testing a treatment for melanoma that has spread to the liver. They collect tumor-infiltrating lymphocytes, a type of immune cell, from the patient's own tumor and grow them in the lab. Before returning the cells, they use a technique called percutaneous hepatic p…

This early-stage trial tests whether immune cells taken from a patient's own tumor (TIL) can be safely given directly into the liver or through a vein to fight metastatic melanoma. 18 adults with advanced uveal or cutaneous melanoma that has spread will receive TIL along with che…

This phase II trial tests whether the chemotherapy drug temozolomide can shrink tumors in people with advanced or metastatic melanoma that has a mutation in the BAP1 gene. BAP1 normally helps repair damaged DNA, and when it is faulty, cancer cells may become more sensitive to cer…

This early-phase trial tests a combination of three immune cell therapies—CAR T cells, cytotoxic T lymphocytes (CTLs), and dendritic cell vaccines—against advanced melanoma that has not responded to standard treatment. The study aims to see if this approach is safe and can shrink…

This study tests whether a new drug called Bmab1700 works the same as the approved immunotherapy Opdivo in people with melanoma who have had their tumors surgically removed. The trial will involve 120 adults with stage IIB to IV melanoma. Researchers will compare how the drugs mo…

This study tests a combination of two immunotherapy drugs, nivolumab and relatlimab, in people with advanced melanoma that hasn't been treated before. The goal is to see if the combination is safe and helps shrink tumors. About 30 adults and teens (ages 12 and up) in India will t…

This phase 2 trial is investigating whether giving immunotherapy before surgery for advanced melanoma (stage IIIB to IV M1a) can maintain survival while allowing patients to skip the usual adjuvant therapy after surgery. Participants are randomly assigned to receive either two in…

This trial investigates whether a sensitive blood test (Signatera) can detect when it is safe to pause immunotherapy in people with advanced solid tumors like lung cancer, melanoma, and colorectal cancer. Participants are randomly assigned to either continuous standard immunother…

This study tests a new drug, prifetrastat, combined with fulvestrant for people with advanced HR+/HER2- breast cancer that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. About 51 participants will receive the combination to see if it can shrink tumors o…

This study looks at whether giving immunotherapy infusions in the morning improves outcomes for people with advanced melanoma. Researchers will compare morning versus afternoon/evening dosing in 108 participants. The goal is to see if aligning treatment with the body's natural im…

This trial investigates whether a single ultra-low dose of rituximab can safely manage immune-related side effects caused by checkpoint inhibitor therapy in people with malignant melanoma. Participants receive one 100 mg infusion of rituximab along with a steroid tapering plan an…

This pilot study explores whether a special PET/CT scan that tracks CD8 immune cells can help select the best tumors for harvesting immune cells (TILs) to treat stage IV melanoma. Participants receive the TIL therapy lifileucel (AMTAGVI) after a chemotherapy regimen. The goal is …

This study tests a therapy called Perkileucel, made from a patient's own immune cells (tumor-infiltrating lymphocytes). These cells are collected from a surgically removed melanoma tumor, grown in a lab, and then infused back into the patient. Before the infusion, patients receiv…

This study tests whether giving a Pfizer-BioNTech COVID-19 mRNA vaccine before standard immunotherapy (pembrolizumab) and chemotherapy can improve outcomes for people with stage 4 non-small cell lung cancer. Researchers will enroll 500 adults to see if the vaccine helps the immun…

This study tests a treatment called extracorporeal photopheresis (ECP) for people with advanced melanoma who develop severe colitis or hepatitis from immunotherapy. ECP filters a patient's blood, treats it with a light-activated drug, and returns it to the body. The trial compare…

This study tests a new drug called Bmab1800 to see if it works like the approved drug Keytruda in people with stage IIB, IIC, or III melanoma after their tumor has been removed by surgery. About 138 adults will get either Bmab1800 or Keytruda, and researchers will compare how the…

This early-phase study tests a new mRNA medicine (NCP-IL-22BP mRNA) in 9 people with advanced solid tumors that have not responded to standard treatments. The medicine is injected directly into tumors to help the body fight cancer. The main goal is to check safety and find the ri…

This early-phase trial tests a virus called DNX-2401, designed to infect and destroy melanoma cells in the brain and body. About 50 adults with stage IV melanoma will receive injections to find the safest dose and number of treatments. The main goal is to check for side effects, …

This phase II trial tests two drugs—SHR-1701 (an immunotherapy) and famitinib (which cuts off tumor blood supply)—given before surgery for resectable mucosal melanoma, a rare and aggressive skin cancer. After surgery, treatment is tailored based on how well the tumor responded. T…

This phase 2 trial tests three immune-boosting drugs (cemiplimab, fianlimab, and ipilimumab) given before surgery in 20 people with advanced but removable melanoma. The goal is to see if the combination is safe and can shrink tumors, potentially improving outcomes. Participants m…

This study tests whether giving three drugs (pucotenlimab, lenvatinib, and temozolomide) before surgery can shrink tumors in people with a specific type of skin cancer called acral melanoma, which is stage IIB or III and can be removed. About 30 adults will receive the drug combi…

This Phase 2 trial tests a new cell therapy called RAPA-201 for people with advanced melanoma that has stopped responding to PD-(L)1 inhibitors. The therapy uses a patient's own immune cells, modified to resist the drug rapamycin, and is given along with chemotherapy. The study a…

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…

This Phase 2 trial tests whether a personalized cell therapy called HS-IT101 works better than chemotherapy for people with advanced melanoma that has stopped responding to standard treatments. HS-IT101 uses a patient's own immune cells, grown in large numbers in a lab, to fight …

This early-stage trial tests an experimental drug called ACC-1898, taken as a daily pill, in adults with advanced solid tumors (like liver, kidney, or stomach cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see how the body handl…

This phase 3 trial tests whether a magnetic tracer (Magtrace) works as well as the standard radioactive dye plus blue dye for finding sentinel lymph nodes in people with melanoma. About 254 adults having surgery for melanoma will receive both tracers and be randomly assigned to h…

This study tests whether a new MRI contrast agent, gadopiclenol, can detect brain metastases earlier than standard methods in 180 patients with advanced lung, breast, or skin cancer. Participants will receive screening brain MRIs to compare diagnosis timing and accuracy. The goal…

This study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…

This study is developing a blood test called NeutroFlow that measures specific immune cells (neutrophils) to predict whether cancer patients will benefit from immunotherapy. Researchers will collect blood samples from 600 patients with several types of cancer before they start tr…

Researchers are testing whether a single high dose of psilocybin, given alongside a structured talking therapy called PEARL, reduces depressive symptoms in adults with advanced cancer. The trial enrolls 46 people in Ontario with stage IV solid tumors, sarcoma, melanoma, endocrine…

This trial tests whether injecting Botox (abobotulinumtoxin-A) into the forehead muscles just before paramedian forehead flap surgery can improve the cosmetic appearance of the resulting scar. Adults with nasal skin cancer defects needing this reconstruction are randomly assigned…

This pilot study tests whether using bright light therapy for an hour each morning, delivered through an iPad app, is tolerable for people with advanced melanoma or non-small cell lung cancer who are about to start immunotherapy. The idea is that synchronizing the body's internal…

This pilot trial tests whether adding emotional support to a cancer information website helps young adults (ages 20-39) with thyroid, melanoma, or testicular cancer feel less worried and distressed. 142 participants will either get general cancer info or the same info plus person…

This study tests whether having melanoma patients regularly report their symptoms through an electronic tool, combined with quick access to specialist care, can improve the management of side effects from immune checkpoint inhibitors. These drugs can cause immune-related side eff…

This study looks at whether intermittent fasting is safe and doable for people with advanced solid tumors who are starting immunotherapy. About 90 participants will be split into three groups: no fasting, eating only during an 8-hour window each day, or fasting every other day. R…

This early-phase trial tests whether a home-based morning light therapy program can help people with advanced melanoma who are receiving tumor-infiltrating lymphocyte (TIL) therapy. The light therapy is delivered through an iPad app and aims to improve the body's natural sleep-wa…

This early-phase study tests whether adding malic acid (a natural fruit acid) to standard immunotherapy is safe for people with solid tumors like colorectal, lung, or melanoma cancer. About 30 participants will take malic acid by mouth while continuing their immunotherapy. The ma…

This pilot study tests whether a personalized exercise and education program, given before and after surgery, can help melanoma patients regain strength and function. Thirty adults with melanoma who are scheduled for surgery after chemotherapy will take part. The main goal is to …

This study screens up to 1,000 people with personal or family histories of certain cancers to see if they qualify for ongoing genetics research at the National Cancer Institute. Participants fill out a 15-20 minute online survey about their health and family history. No treatment…

Researchers are testing whether a PET scan that highlights CD8 immune cells can show the best place to collect tumor-infiltrating lymphocytes (TILs) from patients with advanced melanoma. Participants receive standard TIL therapy and also undergo an extra tumor sample from the sit…

Researchers are studying whether the mix of bacteria in a person's gut can predict how well they respond to immunotherapy drugs called immune checkpoint inhibitors. The trial enrolls about 360 adults with advanced non-small cell lung cancer, melanoma, endometrial cancer, or cervi…

This study looks at whether clinical, pathological, and molecular features can predict how well people with metastatic melanoma respond to first-line immunotherapy. Researchers will collect and analyze data from about 200 patients treated at the European Institute of Oncology wit…

This study compares two total body photography systems used to screen for melanoma, a serious skin cancer. One system, Deviskan, takes automated images with non-contact dermoscopy, while the other, Vectra WB360, uses 3D photography with manual dermoscopy. Researchers will ask 60 …

This study will test whether immunotherapy drugs (immune checkpoint inhibitors) change how the liver processes other medications. About 80 adults with various cancers who are starting immunotherapy will take a low-dose cocktail of 7 common drugs. Researchers will measure drug lev…

This study tests whether an online training platform called DermLoop Learn can improve how pathologists diagnose melanoma from skin lesion images. 258 pathologists will be randomly assigned to receive the training or not, and their diagnostic accuracy will be compared against a p…

This study tests a paper-based decision aid designed to help people with intermediate-risk melanoma decide whether to have a sentinel lymph node biopsy. The tool provides clear information about the procedure, its risks and benefits, and helps patients think about their personal …

This early-phase study tests whether a low-dose immunotherapy injection directly into the tumor can activate the immune system as effectively as standard high-dose treatment through the veins, but with fewer side effects. About 18 adults with advanced melanoma will receive either…

This study looks at whether eating more fiber helps melanoma patients respond better to immunotherapy. Researchers will track the fiber intake of 60 patients using a special questionnaire and see if those who eat more fiber have less cancer recurrence or progression. The goal is …

This study looks at whether tiny particles in the blood, called extracellular vesicles, can help doctors predict if immunotherapy will work for people with advanced lung cancer or melanoma. Researchers will collect blood samples from 378 patients before and during standard treatm…

This study looks at how fat cells and immune cells interact in melanoma skin cancer to see if this can predict whether the cancer will spread. Researchers will examine tissue samples from 20 patients to check for a specific pattern they noticed in earlier work. The goal is to bet…

This study looks at whether older adults (75+) with early-stage melanoma can safely skip an extra lymph node biopsy after their main surgery. The goal is to see if the simpler surgery alone works just as well and improves overall well-being. About 428 participants will be followe…